Cerdulatinib for treating hematological cancers

1. A composition comprising cerdulatinib, or a pharmaceutically acceptable salt thereof, and venetoclax, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient, wherein cerdulatinib and venetoclax are present in a mole ratio of about 2:1 to about 1:5.

2. A method for treating a hematologic cancer in a patient in need thereof, comprising administering to the patient an effective amount of cerdulatinib, or a pharmaceutically acceptable salt thereof, and an effective amount of venetoclax, or a pharmaceutically acceptable salt thereof, wherein cerdulatinib and venetoclax are administered in a mole ratio of about 2:1 to about 1:5.

3. A method for treating a hematologic cancer in a patient in need thereof, comprising administering to the patient the composition of claim 1 .

4. The method of claim 2 , wherein the hematologic cancer is non-Hodgkin's lymphoma (NHL).

5. The method of claim 2 , wherein the hematologic cancer is selected from Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma (FL), transformed Follicular Lymphoma (tFL), Diffuse Large B-cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma, Mucosa-Associated Lymphoid Tissue (MALT), and Waldenstrom Macroglobulinemia (WM).

6. The method of claim 5 , wherein the hematologic cancer is CLL.

7. The method of claim 5 , wherein the hematologic cancer is DLBCL.

8. The method of claim 5 , wherein the hematologic cancer is SLL.

9. The method of claim 2 , wherein cerdulatinib and venetoclax are administered concurrently or sequentially.

10. The method of claim 2 , wherein the patient has a drug resistant and/or relapsed form of the hematologic cancer.

11. The method of claim 10 , wherein the patient has a mutation linked to relapse and/or a resistance to another drug for treating a hematologic cancer.

12. The method of claim 10 , wherein the patient has a resistance to a chemotherapeutic agent.

13. The method of claim 2 , wherein the patient was previously administered a drug selected from an alkylating agent, an anti-CD20 antibody, a BCL-2 inhibitor, a BTK inhibitor, a P13Kδ inhibitor, a platinum-based drug, an antimetabolite, an anthracycline, a BCR pathway inhibitor, and another chemotherapeutic agent used for treating a hematologic cancer.

14. The method of claim 2 , wherein the patient was previously administered a drug selected from venetoclax, rituximab, ibrutinib, idelalisib, and fludarabine.

15. The method of claim 2 , wherein the patient expresses a Bcl-2 protein.

16. The method of claim 2 , wherein the patient expresses a Bim protein.

17. The method of claim 2 , wherein the effective amount of cerdulatinib, or a pharmaceutically acceptable salt thereof, is about 25 mg to about 120 mg administered daily.

18. The method of claim 2 , wherein the effective amount of cerdulatinib, or a pharmaceutically acceptable salt thereof, is about 25 mg to about 50 mg administered twice daily.

19. The method of claim 2 wherein the effective amount of cerdulatinib, or a pharmaceutically acceptable salt thereof, is about 40 mg to about 50 mg administered twice daily.

20. The method of claim 2 , wherein the effective amount of cerdulatinib, or a pharmaceutically acceptable salt thereof, is about 45 mg administered twice daily.

21. The method of claim 2 , wherein the effective amount of cerdulatinib, or a pharmaceutically acceptable salt thereof, is about 35 mg administered twice daily.

22. The method of claim 2 , wherein the effective amount of cerdulatinib, or a pharmaceutically acceptable salt thereof, is about 30 mg administered twice daily.

23. The method of claim 2 , wherein the effective amount of cerdulatinib, or a pharmaceutically acceptable salt thereof, is about 30 mg to about 40 mg administered twice daily.

24. The method of claim 2 , wherein the effective amount of cerdulatinib, or a pharmaceutically acceptable salt thereof, is about 30 mg to about 45 mg administered daily.